HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

The oncogenic receptor HER2 is overexpressed in many cancers, including up to 20% of breast cancers. Despite the availability of HER2-targeted treatments, patients’ disease often progresses during therapy, underscoring the need for novel treatment strategies. The addition of tucatinib, a reversible,...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Devra, Taylor, Janelle, Willis, Kelsi, Hensley, Kelly, Allred, Sean, Zaval, Margo, Farr, Lauren, Thurman, Robert, Jain, Nishi, Hein, Renee, Ulrich, Michelle, Peterson, Scott, Kulukian, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519189/
https://www.ncbi.nlm.nih.gov/pubmed/37721518
http://dx.doi.org/10.1158/2767-9764.CRC-23-0302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519189/
https://www.ncbi.nlm.nih.gov/pubmed/37721518
http://dx.doi.org/10.1158/2767-9764.CRC-23-0302

Ejemplares similares